OncoMatch/Clinical Trials/NCT05941507
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Is NCT05941507 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including LCB84 and Anti-PD-1 monoclonal antibody for advanced solid tumors.
Treatment: LCB84 · Anti-PD-1 monoclonal antibody — This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population in dose escalation (Phase 1) consists of patients with advanced solid tumors refractory to standard of care, or for whom no standard of care exists. After the MTD and/or RP2D for single agent LCB84 is determined, dose escalation cohorts with select tumor types will be enrolled. Combination LCB84 and anti-PD-1 Ab will be evaluated in dose escalation after a minimum of 2 dose levels of single agent LCB84 have established DLT safety, to determine the MTD and/or RP2D of combination LCB84 and anti-PD-1 Ab, and to continue into dose expansion cohorts in select tumor types.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard of care
advanced solid tumors refractory to standard of care treatment
Cannot have received: systemic antineoplastic therapy
Systemic antineoplastic therapy (including antiestrogen therapy) within 5 half-lives or 4 weeks, whichever is shorter, prior to first dose of the study drug.
Lab requirements
Blood counts
ANC ≥1.5 x 10^9/L (1500/µL), without colony-stimulating factor support for the past 14 days; Platelets ≥100.0 x 10^9/L (100 000/µL); Hemoglobin ≥9.0 g/dL
Liver function
AST ≤2.5 x ULN; ALT ≤2.5 x ULN (AST, ALT ≤5 x ULN if liver metastases present)
Adequate organ function as defined by: Absolute neutrophil count (ANC) ≥1.5 x 10^9/L (1500/µL), without colony-stimulating factor support for the past 14 days; Platelets ≥100.0 x 10^9/L (100 000/µL); Hemoglobin ≥9.0 g/dL; Aspartate aminotransferase (AST) ≤2.5 x ULN; alanine aminotransferase (ALT) ≤2.5 x ULN (AST, ALT ≤5 x ULN if liver metastases present)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cedars Sinai Medical Center · Los Angeles, California
- Dana Farber Cancer Institute · Boston, Massachusetts
- University of Michigan · Ann Arbor, Michigan
- Tennessee Oncology · Nashville, Tennessee
- Mary Crowley Cancer Research · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify